Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival
New data demonstrate ENSPRYNG’s robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder.
New data demonstrate ENSPRYNG's robust and sustained longer-term efficacy in preventing relapses in people with neuromyelitis optica spectrum disorder (NMOSD) More than 70% of people treated with
Investegate announcements from F. Hoffmann-La Roche Ltd, [Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD)Gantenerumab is the first and only anti-amyloid antibody being investigated for subcutaneous administration